River Corporate Advisors
River Corporate Advisors identifies itself as a healthcare investment banking firm serving healthcare service and information technology companies. Its stated services include M&A advisory, capital raising, restructuring, valuation, fairness opinions, and interim CFO work.
What stands out about River Corporate Advisors
River Corporate Advisors publicly presents a healthcare-focused advisory practice for growing and middle-market healthcare services, healthcare IT, and related businesses. Its services include sell-side and buy-side M&A, strategic advisory, capital raising, restructuring, special situations, valuations, fairness opinions, and interim CFO services. The sources cited for this profile do not establish a formal geographic mandate, universal financial-size threshold, standard engagement terms, or firm-level regulatory registration status.[1][2][7][8]
What does River Corporate Advisors do?
River Corporate Advisors identifies itself as a healthcare investment banking firm serving healthcare service and information technology companies. Its public materials describe work for growing and middle-market healthcare businesses and include M&A advisory, capital raising, strategic advisory, restructuring, valuation, fairness opinions, and interim CFO services.
The firm’s transaction history includes examples displayed on its official materials, but the company overview states that some transactions were executed by bankers while they were at other firms. Owners evaluating an engagement should distinguish current-firm assignments from predecessor-firm transactions.[1][2]
River Corporate Advisors publicly lists strategic advisory, mergers and acquisitions, joint ventures and affiliations, operational and financial restructuring, pre-transaction consulting and valuations, fairness opinions, and interim CFO services.
The March 2026 company overview additionally describes exclusive sell-side advisory and buy-side advisory, corporate development, special situation advisory, balance-sheet and financial restructuring, in- and out-of-court bankruptcies, distressed M&A, valuation and fairness opinions, and interim CFO services.[1][2]
Owners comparing advisory firms can also review Auxo’s M&A advisor vs. business broker vs. investment bank comparison, advisor-selection guide, and sell-side advisor evaluation framework.
What should a business owner evaluate before hiring River Corporate Advisors?
An owner of a healthcare services, healthcare IT, or related company evaluating River Corporate Advisors can examine its stated sector focus and its coverage of sell-side M&A, capital raising, restructuring, fairness opinions, and special situations. Public examples include regulated healthcare businesses, distressed processes, strategic transactions, and a marketed sale process.
Before engagement, the owner should confirm which named transactions were completed by River Corporate Advisors itself, which members of the proposed team led comparable assignments, the intended buyer universe and geographic reach, engagement fees and tail provisions, valuation methodology, conflicts procedures, and the applicable legal-entity and regulatory framework. The sources cited for this profile do not establish standard answers to those points.[1][2][7]
What are the proposed engagement’s fees, success-fee mechanics, expense policy, tail period, termination rights, and exclusivity provisions
What size transactions and clients does River Corporate Advisors focus on?
The firm states that it assists growing and middle-market healthcare service and information technology companies, including technology-enabled and innovative healthcare businesses.
Its public sector descriptions include healthcare technology, technology-enabled services, medical groups, long-term care, provider organizations, healthcare payers, diagnostic imaging, managed care, hospice, disease management, medical devices, pharmaceuticals and life sciences, and outpatient care. Roberta Hurst’s biography identifies a focus on healthcare technology, technology-enabled services, and related healthcare verticals.[1][3]
Official and SEC-filed materials identify River Corporate Advisors in several public transactions. An SEC-filed document identifies River Corporate Advisors, LLC as the exclusive financial advisor to Speranza in a proposed merger with Odyssey. A registration-statement exhibit identifies the firm as the provider of a fairness opinion to Peak Bio in connection with its merger with Akari Therapeutics, with the opinion dated March 3, 2024. Another SEC-filed document states that the Vaso board obtained a fairness opinion from River Corporate Advisors LLC regarding its proposed business combination with Achari.
The firm’s official materials also display examples including Ignyte, KP, OpenMRI, Holisticare, and Evergreen, while noting that some transaction-history items were completed by RCA officers at prior firms.[1][2][4][5][6]
River Corporate Advisors’ stated transaction work covers sell-side and buy-side M&A, corporate development, capital raising, strategic advisory, joint ventures and affiliations, special situations, restructuring, distressed M&A, valuations, and fairness opinions.
Publicly identified assignments include Reliant Care’s buy-side acquisition program, Optimal Radiology’s exclusive sale and fairness opinion, DiabetesAmerica’s 363 sale process, Fusion Diagnostic Group’s sale to CPMC/Sutter Health, and River Oaks Imaging’s sale to Memorial Hermann Healthcare.[1][2]
What does River Corporate Advisors publicly disclose about fees, process and engagement terms?
The cited official home page does not state a formal geographic coverage mandate or target-region list. The cited March 2026 company overview describes client types and healthcare sectors but does not publish a universal revenue, EBITDA, enterprise-value, transaction-size, or minimum-client-size threshold.
The cited official transaction-history page does not disclose transaction values, consideration terms, buyer identities, or exact closing dates for the displayed transaction examples. The cited official home page does not state standard advisory fees, success-fee percentages, minimum fees, tail periods, termination provisions, or other universal engagement terms. It also does not identify a firm-level broker-dealer, investment-adviser, or other regulatory registration status.[1][2][7]
SEC-filed transaction documents identify River Corporate Advisors or River Corporate Advisors, LLC as a financial advisor or fairness-opinion provider in specific transactions involving Speranza and Odyssey, Peak Bio and Akari Therapeutics, and Vaso and Achari.
The cited official home page does not identify a firm-level broker-dealer, investment-adviser, or other regulatory registration status. It states that the team has experience with regulators and transactions requiring healthcare and governmental approvals, but that statement does not establish a firm-level registration status.[1][4][5][6]
In its River Oaks Imaging case study, River Corporate Advisors states that it sent a teaser to 78 prospective partners, executed confidentiality agreements and sent an information memorandum to 24 parties, received 10 initial indications of interest, invited six parties into diligence, received four second offers, and selected a final bidder.
This case study provides one public example of a marketed transaction process; it does not establish that every engagement follows the same sequence or uses the same outreach scope.[2]
Questions to ask before hiring River Corporate Advisors
Which named transactions were completed by River Corporate Advisors, LLC itself rather than by personnel at prior firms?
What recent sell-side healthcare transactions has the proposed team closed in the last 24 months?
What are the proposed engagement’s fees, success-fee mechanics, expense policy, tail period, termination rights, and exclusivity provisions?
What revenue, EBITDA, enterprise-value, transaction-size, or other criteria determine whether River Corporate Advisors accepts an engagement?
Which geographic markets and buyer categories will be covered for the proposed assignment?
Does the firm or any affiliate maintain broker-dealer, investment-adviser, valuation, or other regulated status relevant to the proposed assignment?
How are fairness opinions, valuation analyses, conflicts, and independence handled?
Sources & research notes
- Official website / firm overview
- Services / capabilities
- Industry / market focus
- SEC filing / regulatory record
- SEC filing / regulatory record
- SEC filing / regulatory record
- Public disclosure information
- Services / capabilities
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.